Mr. Stephen Mulvany:

What we do buy in bulk are the drugs hospitals and community services utilise. The costs about which we are talking largely are those which are reimbursed by the primary care reimbursement service. It is people going into individual pharmacies. The pharmacies require the drugs and what we have, in effect, is a bulk agreement on price with the IPHA which, as the director general mentioned, has delivered €400 million in savings since October 2012. This has allowed us to invest €210 million in new drugs which we would not otherwise have been able to afford. That is the bulk element. That is us dealing with the entire market in terms of the reimbursement of drugs where individuals go into pharmacies. Obviously, we do not buy the drugs directly but reimburse patients through the primary care reimbursement service.